16.59
-0.49 (-2.87%)
| Previous Close | 17.08 |
| Open | 17.00 |
| Volume | 4,405,812 |
| Avg. Volume (3M) | 2,780,711 |
| Market Cap | 2,099,515,136 |
| Price / Sales | 3.08 |
| Price / Book | 2.58 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -25.14% |
| Operating Margin (TTM) | -31.33% |
| Diluted EPS (TTM) | -1.30 |
| Quarterly Revenue Growth (YOY) | 9.80% |
| Total Debt/Equity (MRQ) | 11.33% |
| Current Ratio (MRQ) | 5.37 |
| Operating Cash Flow (TTM) | 56.74 M |
| Levered Free Cash Flow (TTM) | 95.16 M |
| Return on Assets (TTM) | -12.43% |
| Return on Equity (TTM) | -22.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Mixed |
| Health Information Services (Global) | Bearish | Mixed | |
| Stock | 10x Genomics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China). |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Value |
| % Held by Insiders | 1.93% |
| % Held by Institutions | 101.82% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 22.00 (Barclays, 32.61%) | Buy |
| Median | 19.00 (14.53%) | |
| Low | 14.00 (UBS, -15.61%) | Hold |
| Average | 18.14 (9.34%) | |
| Total | 2 Buy, 5 Hold | |
| Avg. Price @ Call | 16.08 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 15 Dec 2025 | 22.00 (32.61%) | Buy | 15.76 |
| 07 Nov 2025 | 17.00 (2.47%) | Buy | 15.25 | |
| Citigroup | 11 Dec 2025 | 18.00 (8.50%) | Hold | 16.54 |
| Morgan Stanley | 02 Dec 2025 | 20.00 (20.55%) | Hold | 17.94 |
| Piper Sandler | 11 Nov 2025 | 19.00 (14.53%) | Hold | 16.59 |
| Canaccord Genuity | 07 Nov 2025 | 19.00 (14.53%) | Buy | 15.25 |
| JP Morgan | 07 Nov 2025 | 15.00 (-9.58%) | Hold | 15.25 |
| UBS | 07 Nov 2025 | 14.00 (-15.61%) | Hold | 15.25 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 18 Nov 2025 | Announcement | New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium |
| 11 Nov 2025 | Announcement | 10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025 |
| 06 Nov 2025 | Announcement | 10x Genomics Reports Third Quarter 2025 Financial Results |
| 29 Oct 2025 | Announcement | 10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research |
| 20 Oct 2025 | Announcement | 10x Genomics and Anthropic Partner to Make Single Cell and Spatial Analysis More Accessible Through Claude for Life Sciences |
| 09 Oct 2025 | Announcement | 10x Genomics to Report Third Quarter 2025 Financial Results on November 6, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |